Glaxosmsc 5.25% Regulatory News (AG99)

Publication of Prospectus

The following Prospectus has been approved by the UK Listing Authority and is available for viewing:

Prospectus dated 3 August, 2011 in relation to GlaxoSmithKline plc; GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. £15 billion Euro Medium Term Note Programme.

To view the full document, please paste the following URL into the address bar of your browser.

http://www.rns-pdf.londonstockexchange.com/rns/6844L_1-2011-8-3.pdf

The documents incorporated by reference can be viewed at www.gsk.com/investors.

For further information, please contact:

GlaxoSmithKline

980 Great West Road

Brentford

Middlesex

TW8 9GS

Enquiries:

BASIS ON WHICH YOU MAY ACCESS THE PROSPECTUS

In accessing the Prospectus, you agree to be bound by the terms and conditions specified in the Important Notice, which appears before the Prospectus, including any modifications to them any time you receive any information from us as a result of such access. The Important Notice does not form part of the Prospectus. The Prospectus shall not be available in any place or to any person except in compliance with all applicable laws and regulations and in circumstances in which no obligation is imposed on GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. or the dealers named in the Prospectus. Prior to accessing the Prospectus you must ascertain that you will be doing so in compliance with such requirement.

The Prospectus comprises a base prospectus for the purposes of Article 5 of Directive 2003/71/EC (the "Prospectus Directive"). It is not a prospectus for purposes of Section 12(a)(2) or any other provision of or rule under the Securities Act of 1933, as amended, of the United States of America.

Your right to access this service is conditional upon complying with the above requirements.